Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A

Published:2020-11-24 Issue:1 Volume:27 Page:81-89
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Shima Midori¹^ORCID,Nagao Azusa²,Taki Masashi³,Matsushita Tadashi⁴,Oshida Koichi⁵,Amano Kagehiro⁶,Nagami Sayaka⁷^ORCID,Okada Norihiro⁷,Maisawa Shingo⁷,Nogami Keiji¹^ORCID

Affiliation:

1. Department of Pediatrics Nara Medical University Kashihara Japan

2. Department of Blood Coagulation Ogikubo Hospital Tokyo Japan

3. Department of Pediatrics St Marianna University School of Medicine Kawasaki Japan

4. Department of Transfusion Medicine Nagoya University Nagoya Japan

5. Department of Pediatrics University of Occupational and Environmental Health Kitakyushu Japan

6. Department of Laboratory Medicine Tokyo Medical University Tokyo Japan

7. Chugai Pharmaceutical Co., Ltd. Tokyo Japan

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14205

Reference24 articles.

1. Guidelines for the management of hemophilia

2. A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management

3. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

4. Early Prophylaxis Provides Continued Joint Protection in Severe Hemophilia A: Results of the Joint Outcome Continuation Study

5. Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review;Research and Practice in Thrombosis and Haemostasis;2024-05

2. Expert Opinions on the Management of Hemophilia A in India: The Role of Emicizumab;Cureus;2024-04-24

3. Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis;Sao Paulo Medical Journal;2024

4. Long-term efmoroctocog alfa prophylaxis improves perceived pain, mental, and physical health in patients with hemophilia A: post hoc analysis of phase III trials using patient-reported outcomes;Therapeutic Advances in Hematology;2024-01

5. Paradigm shifts in haemophilia A therapy with emicizumab prophylaxis in Asia;Annals of the Academy of Medicine, Singapore;2023-11-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3